CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT04381741 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

BIOLOGICAL: CD19-7×19 CAR-T plus PD1 monoclonal antibody

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University